RadioMedix Marks 20 Years with New Pancreatic Cancer Alpha Therapy

HOUSTON, TX – May 28, 2026 – As the radiopharmaceutical field gains unprecedented momentum, Houston-based RadioMedix, Inc. is set to mark its 20th anniversary by showcasing significant advances in cancer-fighting technology at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles. The clinical-stage company will present promising new data on a targeted alpha therapy for pancreatic cancer, one of the most lethal malignancies, reinforcing its two-decade legacy of tackling difficult-to-treat diseases.

A Dual Milestone at SNMMI 2026

RadioMedix's participation in the premier nuclear medicine conference, running from May 30 to June 2, serves as both a scientific showcase and a corporate milestone. The company's leadership will lead two key sessions focused on the development of lead-212 (²¹²Pb), a potent alpha-emitting isotope at the vanguard of next-generation cancer treatments.

Ebrahim S. Delpassand, M.D., the company's founder and Chief Executive Officer, will discuss the clinical applications of ²¹²Pb in an Emerging Technology session. His presentation is expected to highlight the isotope's potential to create more effective and precise radiopharmaceutical drugs.

In a separate session, Izabela Tworowska, Ph.D., RadioMedix's Co-Founder and Chief Scientific Officer, will unveil preclinical data for a novel therapy targeting pancreatic ductal adenocarcinoma (PDAC). This presentation will offer the first detailed look at the biodistribution, tumor response, and tolerability of ²¹²Pb-RMX-VH-PKM, a second-generation radioconjugate developed to seek and destroy pancreatic cancer cells.

The timing of these presentations is particularly significant as RadioMedix celebrates 20 years of innovation. Founded in 2006, the company has been a persistent force in a field that is now capturing widespread attention from the broader medical and investment communities.

“SNMMI has long been an important forum for scientific exchange and progress in nuclear medicine, making it a meaningful setting to share our latest work and mark RadioMedix’s 20-year journey,” said Dr. Delpassand in a statement. “When we founded RadioMedix, our goal was to help bring the promise of targeted radiopharmaceuticals closer to patients with difficult-to-treat cancers. Over the past two decades, that mission has guided our work across discovery, isotope supply, manufacturing, and clinical development.”

Targeting Pancreatic Cancer's Unmet Need

The focus on pancreatic ductal adenocarcinoma (PDAC) underscores RadioMedix's commitment to addressing areas of high unmet medical need. PDAC is notoriously aggressive and resistant to conventional treatments, with a five-year survival rate that remains stubbornly low. Its tendency to metastasize early and evade standard chemotherapy regimens has left a critical gap in oncology, creating an urgent need for novel therapeutic strategies.

Targeted Alpha Therapy (TAT) represents one such strategy. The approach presented by Dr. Tworowska uses a peptide to home in on the low-density lipoprotein receptor (LDLR), which is overexpressed on pancreatic cancer cells. Once attached, the therapy delivers a highly potent dose of alpha radiation directly to the tumor from its lead-212 payload.

“At RadioMedix, our scientific work has always been closely tied to patient need,” noted Dr. Tworowska. “Our participation at SNMMI this year is an opportunity to share progress from our team, engage with the broader nuclear medicine community, and recognize the importance of continued innovation in targeted radiopharmaceuticals.”

The preclinical data from PDAC models is a crucial first step, demonstrating whether the drug can effectively find its target, shrink tumors, and be tolerated before moving into human clinical trials. A positive outcome could represent a new beacon of hope for patients facing a grim prognosis.

The Power and Promise of Alpha Emitters

The technology at the heart of RadioMedix's latest work, Targeted Alpha Therapy, is considered one of the most powerful tools in the nuclear medicine arsenal. Unlike beta particles used in other radiotherapies, alpha particles are heavy and release a large amount of energy over a very short distance—typically just a few cell diameters. This allows them to inflict irreparable double-strand DNA breaks in cancer cells with surgical precision, minimizing damage to surrounding healthy tissue.

Lead-212 is emerging as a particularly attractive isotope for TAT. With a 10.6-hour half-life, it is long-lasting enough for manufacturing and delivery to patients but short enough to limit prolonged radiation exposure. Critically, it acts as an in vivo generator, decaying into Bismuth-212, which releases the cell-killing alpha particle directly at the tumor site. This unique decay profile, combined with the potential for a stable supply chain, has positioned ²¹²Pb as a leading candidate to fuel the next wave of radiopharmaceutical approvals.

The market for these advanced therapies is expanding rapidly. The global radiopharmaceuticals market, valued at over $6.7 billion in 2024, is projected to more than double by 2033. The targeted alpha therapy segment, specifically, is forecast to grow at a compound annual rate of over 40% through 2030, reflecting intense scientific interest and investment from companies like Novartis, Bayer, and a growing number of specialized biotechs.

Two Decades of Radiopharmaceutical Leadership

While the field is now booming, RadioMedix has been a foundational player for two decades. The company's history is marked by early clinical leadership that helped validate therapies now considered standards of care. Dr. Delpassand was instrumental in providing U.S. patients with early access to Lutetium-177 dotatate and Lutetium-177 PSMA-617 through physician-sponsored trials, years before they became the blockbuster FDA-approved drugs Lutathera and Pluvicto, respectively.

This track record of clinical translation is supported by a robust infrastructure. In 2018, the company established The SPICA Center, a 27,000-square-foot, state-of-the-art manufacturing facility north of Houston. The cGMP-compliant center gives RadioMedix end-to-end control over its drug development, from isotope generation to final production. This vertical integration is a significant strategic advantage in an industry often plagued by isotope shortages and supply chain bottlenecks. The facility has already played a role in mitigating global shortages of other medical isotopes and is equipped with proprietary technology like the Raha-100, an automated synthesizer for producing lead-212, ensuring a reliable supply for its clinical programs.

The company’s pipeline reflects this blend of experience and innovation. Its diagnostic agent, Detectnet (copper Cu 64 dotatate), gained FDA approval in 2020 for imaging neuroendocrine tumors. More recently, its lead alpha-therapy candidate, 212Pb-Dotamtate, received a Breakthrough Therapy Designation from the FDA in 2024 for treating neuroendocrine tumors, signaling its potential for a substantial improvement over available therapies. The upcoming presentations at SNMMI 2026 build on this momentum, expanding the company's alpha therapy platform into another challenging cancer indication.